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We have investigated the prevalence of the Leiden mutation and a 3.0% rate of carriers of the Leiden mutation. These in a population of women in Berlin, Germany, with pregnancyresults indicate a significantly higher prevalence of both induced hypertension (PIH) in order to compare this prevalence APC resistance and factor V Leiden mutation in women with carrier rates in a group of normotensive women and with with severe PIH. Placental infarctions and micro-embolisms rates quoted in other studies (Dekker et al., 1995;  Dizonare considered to be one of the principle pathophysiological Townson et al., 1996; Lindoff et al., 1997) . Additionally, we changes in severe PIH. Our results suggest that APC looked for common clinical characteristics of women with PIH. resistance is a risk factor for severe PIH, in addition to its well-known role in macrothrombo-embolism. Key words: APC resistance/factor V Leiden mutation/placental Materials and methods infarction/pre-eclampsia/pregnancy-induced hypertension The factor V Leiden mutation is the most common genetic All women had PIH according to the diagnostic criteria described cause of resistance to activated protein C (APC) and has by the German Section of the International Society for the Study of recently been associated with severe pre-eclampsia (Dekker Hypertension in Pregnancy (ISSHP): PIH was defined as hypertension Dizon-Townson et al., 1996; Lindoff et al., 1997) without proteinuria which occurs after the 20th gestational week and and other obstetric complications (Kupferminc et al., 1999) . PIH including those with pre-eclampsia and HELLP syndrome had participants were interviewed about their blood pressure, their current Ͼ4 17.1 (n ϭ 12) 16.0 (n ϭ 16) medication, and their personal and family history of thrombo-embolic events. Additionally, medical charts were reviewed and patient demographics including age, weight, height, gravidity, parity, mode of delivery and personal and family history of hypertension, were recorded. Fetal outcome data including sex, weight, length, head pooled plasma was used. The clotting times (in seconds) were circumference, Apgar scores, umbilical artery and vein pH were plotted in the log/log divided co-ordinate scheme. The percentage of tabulated.
AK-INAKT for the clotting times of the patients' plasma in seconds was read off from the curve. Control group A control group was established to find out the prevalence of APC resistance in a group of normotensive pregnant women. Between
Results
January and May 1998, blood from 100 pregnant women was drawn during ante-natal visits to the Department of Delivery for routine APC resistance frequencies of 10.0% (7/70) in the PIH group tests. These women did not have elevated blood pressure, i.e. not The two study groups were well matched and there were von Willebrand antigen, ristocetin cofactor, protein C and S, APC resistance and accelerin inactivation. no significant differences regarding gravidity (Table I) . The median maternal age in the PIH group was 28 years (range Turkey (12.9%), and one from Yugoslavia (1.4%); seven women (10.0%) were born in other countries. In comparison,
APC resistance and accelerin inactivation test
the control group showed that 77 women originated from APC resistance was determined using the Coatest APC Resistance kit ® Germany (77.0%), 14 women from Turkey (14.0%), three according to the original instructions provided by the manufacturer women from Yugoslavia (3.0%) and six from other countries (Chromogenix, Mölndal, Sweden) . In addition, the accelerin inactivation test was used to detect factor V Leiden-related APC resistance (6.0%).
even in patients undergoing anticoagulation therapy (Hintz et al., In the PIH group the non-carriers of the factor V Leiden 1995). In contrast to the APC procedure, the patients' standard and mutation showed neither antithrombin III nor protein C deficontrol plasmas were diluted 1:20 with barbitol buffer to a pH of 7.6 ciency. Low levels of protein S (Ͻ65%) were measured in 19 (Behringwerke, Marburg/Lahn, Germany) and genuine human factor pregnant women; this finding was consistently present 1-2 V-deficient plasma (Immuno, Heidelberg, Germany) was added. From days post-partum. Thus, this should be regarded as a pregnancyeach patient's blood sample, 50 µl of plasma (1:20 diluted) was induced deficiency of protein S. In the group without APC mixed with 50 µl of factor V-deficient plasma and 50 µl of APTT resistance, 11 had elevated fibrinogen concentrations (Ͼ450 reagent which was then incubated for 7 min at 37°C. Thereafter, mg/dl, maximum: 690 mg/dl) which could be linked to 50 µl of undiluted APC-CaCl 2 solution was added. The times of analysis were measured with the Coa Screener coagulometer (Labor, gravidity. Among women without APC resistance, the median Ahrensburg, Germany).
APC ratio was 2.7 (Ϯ0.4; normal Ͼ2.0) versus a ratio of 2.6
To establish a reference curve, the APC-CaCl 2 solution was diluted (Ϯ0.35) in the control group.
with CaCl 2 in a concentration of 0.025 mol/l. The degree of dilution In the group of women who had PIH and showed APC of the APC solution was defined as accelerin inactivation resistance (Table II) , the median gestational age was 37 Ϯ 3.7 (AK-INAKT) and was described as a percentage. Accordingly, APC weeks (range 30-39), the mean maternal age 29.6 (range 25-solutions of 1:1 (undiluted), 1:2, etc. corresponded to 100%, 50%, 35), the median gravidity 2.4 Ϯ 2.2 (range 1-7) and the etc. AK-INAKT. As a reference standard, pooled plasma from 15 median parity 1.6 Ϯ 0.8 (range 1-3). We found a median healthy blood donors without a history of thrombophilia was used.
diastolic blood pressure of 115 mm Hg. The Caesarean section
The current experimental set-up was similar to that described for previous investigations (Hintz et al., 1995) except that, in this study, rate was 42.9%. BMIϭ body mass index (normal Ͻ25); CNS symptoms ϭ headache, photophobia, hyper-reflexia, hyperemesis, nausea, 1st: PIH ϭ PIH in antecedent pregnancy; HELLP ϭ haemolysis, elevated liver function tests and low platelet count; op ϭ operative; c-section ϭ Caesarean section; spont ϭ spontaneous; BP ϭ blood pressure.
B.S.Horstkamp et al.
Discussion complications. The incidence of factor V Leiden carriers among women with severe pre-eclampsia was 20.0% compared The factor V Leiden mutation as the most common genetic to a rate of 6.0% in a group of women with uneventful cause of resistance to APC is associated with a higher risk of pregnancy. thrombosis Bertina et al., 1994) .
We did not find unexpected laboratory tests within the group Endothelial dysfunction is probably the final pathway of of women with PIH. All values which differed from normal pre-eclampsia (Dekker et al., 1995) . The injury of endothelial values could be explained by physiological changes during cells (Khong and Mott, 1993) as well as placental infarctions pregnancy (Øian, 1997) . Therefore, we did not perform laborat- (Roberts, 1989; Dekker, 1994) have been found in preory tests other than tests for APC resistance, accelerin inactivaeclampsia. During pregnancy, maternal adaptation is responstion and PCR for factor V Leiden mutation in our control group. ible for changes in the coagulation system, which is represented
Other risks for women with the factor V Leiden mutation by increased levels of fibrinogen, factor VII, VIII, IX and X, include an up to 10-fold higher overall risk for thrombosis and a decreased level of plasminogen (Øian, 1997) . Thus, (Koster et al., 1993) , as well as a 30% higher risk for pregnant women are at a generally higher risk of thrombosis.
thrombosis during oral contraception use (Vandenbroucke With this knowledge, it is easy to understand that women with et al., 1994) , and a higher risk for thrombosis during in-vitro a higher genetic risk of systemic thrombosis might have a fertilization (IVF) treatment (Horstkamp et al., 1996a,b) . higher risk of placental infarction as well.
Our investigation indicates a higher prevalence of APC Different rates of APC resistance have been reported. Dekker resistance in women with pregnancy-induced hypertension. As et al. (1995) described a 16% rate of APC resistance in severe APC resistance is linked to thrombosis and other serious early-onset pre-eclampsia and Lindoff et al. (1997) published complications leading to maternal morbidity, our study supports a rate of 22% in women with pre-eclampsia. These diverse the idea of screening tests for APC resistance in women with findings might be explained by the wide variety of the such problems during pregnancy. We suggest that knowledge prevalence of factor V Leiden in populations of different of patients with the factor V Leiden mutation might and should ethnic origin. These prior investigations used a more liberal alter the treatment, e.g. by adding low-dose aspirin and definition for hypertension in pregnancy and focused more on following these women even more closely throughout their pre-eclampsia than pregnancy-induced hypertension. Therepregnancy. However, the high variation of prevalence of the fore, caution should be used when comparing those studies factor V Leiden mutation in different ethnic groups requires with ours.
its definition before screening. Dizon-Townson et al. (1996) found a frequency of 4.2% for APC resistance in a group of 403 normotensive pregnant women. In the same investigation, a heterozygous carrier rate
